SiCare Bio and Agno Pharma Announce Strategic Partnership to Scale Advanced Drug Delivery Platform
Emeryville, CA and Bethlehem, PA (August 27, 2025) – SiCare Bio, a leader in next-generation drug delivery, today announced a strategic partnership with Particle Sciences, Inc., an Agno Pharmaceutical company (Agno), a global Contract Development and Manufacturing Organization (CDMO) serving the pharmaceutical, biotech, generic, and CDMO sectors, to accelerate and scale its proprietary drug delivery platform. Under the collaboration, SiCare Bio and Agno will pursue collaborative opportunities to advance novel therapeutic candidates from early-stage development through clinical and commercial manufacturing.
The SiCare Bio™ drug delivery platform, SiRx™, is being utilized by industry partners to develop custom long acting injectable and intracellular delivery solutions. At the core of these solutions is SiCare Bio’s high-precision, biocompatible nanoporous silica, which is used to encapsulate and deliver target active pharmaceutical ingredients (APIs) into the body. As these therapeutic solutions move through development, Agno will offer SiCare Bio’s development partners an option for scaling production and commercialization.
“The Agno partnership represents an important milestone for SiCare Bio,” said Barry McDonogh, Chief Executive Officer of SiCare Bio. “We are seeing significant demand for our platform on the first nine months of operation. Agno’s expertise and proven operational scale will enable a faster transition from preclinical research to clinical trials and market-ready therapeutics for our development partners.”
“We are thrilled to partnering with SiCare Bio,” said Robert W. Lee, SVP of Business Development of Agno Pharma. “In recent years, there has been a heightened interest in the use of silicon dioxide as a drug delivery vehicle. SiCare Bio’s novel nanoporous silicon dioxide enables parenteral/ophthalmic delivery and offers development partners an attractive solution for safe, precision drug delivery.”
The partnership is expected to initiate joint development programs immediately, with several of SiCare Bio’s development partners already in discussion with Agno.
About SiCare Bio™
SiCare Bio is enabling the next generation of nano-therapeutics through its precision nanoporous silicon dioxide particles. SiCare Bio’s drug delivery platform is utilized by development partners to develop innovative long-acting injectable and intracellular delivery solutions. Underpinning SiCare Bio’s platform is its unique form of high-precision, biocompatible nanoporous silica. Learn more at www.SiCareBio.com.
About Agno Pharma
Agno Pharma is a global Contract Development and Manufacturing Organization (CDMO) specializing in regulatory starting materials (RSMs), intermediates, active pharmaceutical ingredients (APIs), highly potent APIs, sterile APIs, and sterile drug product formulations. Founded in 2004, Agno offers GMP-compliant manufacturing facilities and has expertise in sterile suspension injectables and complex injectables. Agno supports clients throughout the drug development and commercialization process globally. For more information, please visit www.agnopharma.com or contact info@agnopharma.com.